A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
At a glance
- Drugs SVN53-67-M57-KLH peptide vaccine (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 26 Feb 2017 Planned primary completion date changed from 1 Nov 2017 to 9 Nov 2018.
- 22 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.